Biotech · Private company
Oxford BioMedica
Track this companyFree. Adds Oxford BioMedica to your Dealase workspace and tells you when its record changes.
Clinical trials51 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- TrovaxPhase 3 · Clear Cell Renal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 2 · Hormone Refractory Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- IL-2Phase 2 · Carcinoma, Renal CellClinicalTrials.gov · fetched Nov 12, 2026
- Interleukin-2Phase 2 · Carcinoma, Renal CellClinicalTrials.gov · fetched Nov 12, 2026
- TroVaxPhase 2 · Hormone Refractory Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- TroVaxPhase 2 · Carcinoma, Renal CellClinicalTrials.gov · fetched Nov 12, 2026
- RetinoStatPhase 1 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular DegenerationPHASE1 · ACTIVE_NOT_RECRUITING · started Aug 1, 2012ClinicalTrials.gov NCT01678872 · fetched Nov 12, 2026
- TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)PHASE2 · TERMINATED · started Aug 1, 2010ClinicalTrials.gov NCT01194960 · fetched Nov 12, 2026
- TroVax Renal Immunotherapy Survival TrialPHASE3 · COMPLETED · started Sep 1, 2006ClinicalTrials.gov NCT00397345 · fetched Nov 12, 2026
- Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell CarcinomaPHASE2 · COMPLETED · started Nov 1, 2005ClinicalTrials.gov NCT00325507 · fetched Nov 12, 2026
- A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell CancerPHASE2 · COMPLETED · started Aug 1, 2004ClinicalTrials.gov NCT00083941 · fetched Nov 12, 2026